Cargando…

Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis

SIMPLE SUMMARY: Prostate cancer (PCa) represents the most common male urologic neoplasia. In the present study, the authors performed a review of scientific literature to establish the most potentially valuable biomarkers. After this a meta-analysis of two most interesting biomarkers (BRCA 1 and 2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domrazek, Kinga, Pawłowski, Karol, Jurka, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340691/ https://www.ncbi.nlm.nih.gov/pubmed/37444562 http://dx.doi.org/10.3390/cancers15133452

Ejemplares similares

The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors
por: Kaszak, Ilona, et al.
Publicado: (2022)

ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
por: Wang, Da, et al.
Publicado: (2023)

The influence of Mycoplasma species on human and canine semen quality: a review
por: Domrazek, Kinga, et al.
Publicado: (2022)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
por: Lim, Minji, et al.
Publicado: (2018)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
por: Abbosh, Christopher, et al.
Publicado: (2017)

Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
por: Lau, Edmund, et al.
Publicado: (2020)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration
por: Jiang, Xiu-Feng, et al.
Publicado: (2022)

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
por: Yaghoubi Naei, Vahid, et al.
Publicado: (2023)

Prediction of the treatment response in ovarian cancer: a ctDNA approach
por: Sharbatoghli, Mina, et al.
Publicado: (2020)

ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer
por: Escudero, Laura, et al.
Publicado: (2021)

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
por: Abbosh, Christopher, et al.
Publicado: (2023)

Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors
por: Takayasu, Takeshi, et al.
Publicado: (2020)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
por: Mittal, Abhenil, et al.
Publicado: (2023)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

A clinician’s handbook for using ctDNA throughout the patient journey
por: Hasenleithner, Samantha O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e57g219egf84chv47sb5jmtk6i